The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of Icotyde, making it the first oral therapy designed to target the IL-23 receptor, an important driver of inflammation in plaque psoriasis. The recommendation marks a significant advance in the treatment of chronic inflammatory skin diseases.
Plaque psoriasis is a long-term autoimmune condition that causes inflamed, scaly patches on the skin and affects millions of people worldwide. Current advanced treatments often require injections or infusions. An effective oral alternative could improve convenience and treatment adherence for many patients while expanding therapeutic options for physicians.
The EMA's recommendation follows a review of clinical data evaluating the medicine's safety, quality, and effectiveness. The recommendation will now be considered by the European Commission, which is responsible for making the final decision on whether the medicine can be marketed throughout the European Union.
Medical experts say innovations targeting the IL-23 pathway have transformed psoriasis care in recent years. Introducing the first oral medicine in this class could represent another important milestone by giving eligible patients access to an easier-to-administer treatment while maintaining the benefits of targeted immune therapy.
